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Efficacy of the Combination of Pinaverium Bromide 100mg Plus
Simethicone 300mg in Abdominal Pain and Bloating in Irritable
Bowel Syndrome: A Randomized, Placebo-controlled Trial
Max J. Schmulson, MD,*†‡ Jazmin Chiu-Ugalde, MSc,§
Adolfo Sáez-Ríos, MD,∥¶# Aurelio López-Colombo, MD, MSc,**
Gualberto J. Mateos-Pérez, MD,†† José María Remes-Troche, MD, MSc,‡‡
Sergio Sobrino-Cossio, MD,§§∥∥ Julio C. Soto-Pérez, MD,¶¶##
José L. Tamayo de la Cuesta, MD,## Oscar T. Teramoto-Matsubara, MD,†
and Juan C. López-Alvarenga, MD, PhD***†††
Goals: We aimed to evaluate the efficacy and safety of PB+S
(pinaverium bromide 100mg plus simethicone 300mg) in patients
with irritable bowel syndrome (IBS).
Background: IBS is a multifactorial disorder; thus, combination
therapy with different mechanisms of action is expected to be useful.
PB+S has shown effectiveness in an open-label clinical study in IBS.
However, there are no placebo-controlled trials.
Materials and Methods: IBS-Rome III patients with abdominal
pain/discomfort for at least 2 days within the week prior to baseline
assessment were included in this 12-week, randomized, double-
blind, placebo-controlled study of PB+S versus placebo, bid. The
primary endpoint was overall symptom improvement, evaluated
weekly by the patient (Likert Scale). Secondary endpoints included
the weekly improvement in the severity of abdominal pain and
bloating assessed both by patients (10-cm Visual Analogue Scale)
and investigators (Likert Scale); frequency of Bristol Scale stool
types (consistency) evaluated by patients and the IBS Quality of Life
scores.
Results: A total of 285 patients (female: 83%; 36.5± 8.9 y old)
received at least 1 dose of PB+S (n= 140) or placebo (n= 145). No
difference was observed in overall symptom improvement between
the groups (P= 0.13). However, PB+S was superior in abdominal
pain (effect size: 31%, P= 0.038) and bloating (33%, P= 0.019).
Patients with IBS-C and IBS-M showed the best improvement in the
frequency of stool types with PB+S. No differences were observed in
IBS Quality of Life scores and adverse events.
Received for publication March 13, 2019; accepted June 6, 2019.
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Conclusions: PB+S was superior to placebo in improving abdominal
pain and bloating in patients with active IBS. The effect on the
frequency of stool consistency was particularly significant in IBS-C
and IBS-M.
Key Words: irritable bowel syndrome, pinaverium bromide-sime-
thicone, combined therapy, bloating, abdominal pain
(J Clin Gastroenterol 2020;54:e30–e39)
I rritable bowel syndrome (IBS) is a functional bowel dis-order, characterized by abdominal pain and/or discomfort,
associated with changes in bowel habits.1 Diagnosis is cur-
rently performed using Rome IV criteria2,3; however, IBS
prevalence can vary from 1.1% to 45% according to the used
criteria.4,5 In Mexico, 2 different population-based studies
using Rome II criteria have estimated a prevalence of 16%,6,7
whereas a study using Rome III criteria has reported a much
lower prevalence of 4.4%.8 In several studies, IBS has shown a
negative impact on patients’ quality of life (QoL) and is
associated with a significant burden in terms of health-related
direct and indirect costs.9,10
Several plausible pathophysiological mechanisms have
been linked to IBS, including digestive motor disturbances,
visceral hypersensitivity, brain-gut axis dysfunction, low-grade
inflammation in the gut mucosa, immune activation, and
dysbiosis; notwithstanding, most probably IBS is a multi-
factorial disorder.11–14 Nevertheless, most available drug
treatments are directed toward a single mechanism, a single
IBS subtype (eg, IBS-D or IBS-C) and to alleviate isolated
symptoms.15,16 However, as a multifactorial disease, IBS
is likely to require a combination of therapies targeted at
different mechanisms. In fact, the combination of mosapride
with probiotics showed to be effective in relieving symptoms
of nondiarrheal IBS patients.17 Moreover, the combination of
alverine citrate with simethicone, an antispasmodic with an
antiflatulent agent, has been reported to be effective on
abdominal pain/discomfort and on the global symptom
improvement, compared with placebo in patients with IBS.18
More recently, in an on-demand trial, it was shown to sig-
nificantly improve QoL, global symptom severity, and
abdominal pain and bloating, compared with usual
treatments.19
Pinaverium bromide (PB) [N-(bromo-2-dimethoxy-
4,5-benzyl)-N([(dimethyl-6,6 norpinanyl-2)-2 ethoxy]-2 ethyl
morpholinium bromide] is a quaternary ammonium derivative
that acts as an antispasmodic agent by blocking both mus-
carinic receptors20 and calcium channels in the gut smooth
muscle cells. In vitro assays have demonstrated that PB binds
the α-1 subunit21 of L-type (long-lasting)22 voltage-operated
channels, on the external surface of intestinal smooth muscle
cells,23 exerting a calcium-channel inhibition. Calcium entry
into these channels is the main pathway to trigger contractile
activity; thus, by blocking them, an antispasmodic effect is
produced. One of the main features of PB is its poor systemic
absorption and selective pharmacological effects on the gas-
trointestinal tract, rather than the cardiovascular system, thus
providing a high safety profile.24
In contrast, simethicone (S), also known as activated
dimethicone (dimethylpolysiloxane [(CH3)2[Si(CH3)2O]n]),
is a chemically inert compound of silica gel not absorbed in
the gastrointestinal tract. It is physiologically inactive and
nontoxic when used orally. Its antifoaming action has been
studied in vitro, showing that it has the property of
decreasing the surface tension of liquid;25 therefore, it has
been used in vivo to help as a visualization agent during
endoscopy and colonoscopy by preventing bubble formation
and gas retention.26,27 S has been available since the 1960s
as a well-tolerated medication.28–30 However, S alone is not
effective to reduce the median time to complete relieving of
gas-related abdominal discomfort or the median time to last
unformed stool, unless combined with loperamide,31,32 in
patients with acute diarrhea with gas-related abdominal
discomfort.
The effectiveness of 100 mg pinaverium bromide and
300 mg of simethicone (PB+S) as a combination therapy
for IBS has previously been shown in a nationwide open-
label 4-week clinical trial in Mexico.33 In that study, PB+S
improved abdominal pain and bloating in all IBS subtypes
after 4 weeks of treatment. In addition, PB+S improved
stool frequency and consistency in patients with all IBS
subtypes. Therefore, in the current study, we aimed to
assess the efficacy, QoL, and safety profile of PB+S PO,




This was a randomized, double-blind, placebo-con-
trolled, parallel group, multicenter study conducted from
November 2008 to December 2009. Patients were recruited
among those consulting 19 physicians in Mexico (gastro-
enterologists 55.4%, general surgeons 26.6%, and endo-
scopists 18%). Those who met eligibility criteria and vol-
unteered for the study were randomized to either PB+S or
matching placebo for 12 weeks.
Patient Eligibility
Patients were eligible for inclusion if they were
aged18 years or above and 50 years or below, had a body
mass index (BMI) <35 kg/m2, and fulfilled Rome III criteria
for IBS. In addition, patients needed to have active IBS at
enrollment. Active IBS was considered in the presence of
abdominal pain and/or discomfort in at least 2 days during
the week before baseline assessment. Although patients were
recruited independently of the bowel habit subtype, these
were classified according to Rome III as IBS with con-
stipation (IBS-C), diarrhea (IBS-D), mixed (IBS-M), or
unsubtyped (IBS-U). Endoscopic examination (either upper
endoscopy and/or colonoscopy) was optional at the inves-
tigators’ discretion.
Patients were excluded if they had received any treatment
for IBS (eg, pure PB, trimebutine, tegaserod, etc.) within the
last 30 days before the start of the study protocol; if they
presented any alarm symptoms such as anemia, rectal bleed-
ing, unexplained weight loss, general health status impairment;
and if they presented any abnormal laboratory parameters
and/or vital signs considered as clinically relevant by the
investigators. Other exclusion criteria included confirmed or
suspected malignancy in any system or organ; women who
were pregnant or suspected to be pregnant or breastfeeding;
confirmed or suspected rectal or anal stenosis and/or esoph-
ageal varices; history of unspecified ulcerative colitis or
Crohn’s disease, rectal or anal ulcers, or any related compli-
cations and/or celiac disease; history of major upper or lower
abdominal surgery (except for appendectomy), gastrointestinal
tract malformations, or intestinal obstruction; any severe or
unstable organ or systemic condition (eg, diabetes, thyroid
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disease, cardiovascular disorders), history of alcohol or drug
abuse or known allergies to any of the components of the study
combination.
Study Medication
Study medication included 100 mg of pinaverium bro-
mide and 300mg of simethicone (PB+S) packed in gelatine
capsules. PB+S and placebo were provided by Takeda
Mexico SA de CV (formerly Nycomed) and were identical
in shape and color. The assigned treatment was taken twice
a day, 10 to 15 minutes before breakfast and dinner.
Randomization and Blinding
Patients were randomized to either PB+S or placebo in
a 1:1 ratio. Allocation of patients to treatment groups was
carried out using block randomization (blocks of 4). The
randomization scheme (stratified by site) was generated
using the SAS program (SAS Institute Inc., Cary, NC). This
was a triple-blind study, in which all study personnel and
participants and the Statistician (J.C.L.-A.) were blinded to
the true identity of the treatment assigned until statistical
analysis was finalized.
Prohibited Concomitant Medications
Any treatment likely to interfere with the study drug
evaluation was prohibited during the study (eg laxatives,
antidiarrheal medications, and antispasmodics). If abso-
lutely necessary, patients were allowed to use concomitant
treatments for other chronic diseases (eg, controlled diabetes
mellitus, systemic arterial hypertension). In addition,
patients were advised not to change their regular diet
throughout the study period.
Data Collection and Efficacy Endpoints
Study visits were scheduled at randomization (V0,
basal assessment) and then at weeks 4 (V1), 8 (V2), and 12
(V3). Throughout the duration of the study, patients had to
report in a paper diary their evolution in all efficacy end-
points relating to the previous week. In addition, assess-
ments by investigators were performed at each study visit, as
described below.
Primary Efficacy Endpoint
The primary efficacy endpoint was the overall symp-
tom improvement score reported by the patient at the end of
the treatment period (week 12: V3) according to the fol-
lowing statement: ‘The treatment helped to improve my
bowel problems’, using a 5-point Likert Scale (0: strongly
disagree, 1: disagree, 2: neither agree nor disagree, 3: agree,
and 4: strongly agree). Efficacy was considered to be ach-
ieved if the difference between the treatment groups in the
effect size was at least 30%, favoring the PB+S group at V3.
Secondary Efficacy Endpoints
Secondary endpoints included the severity of individual
symptoms (abdominal pain and bloating), frequency of
Bristol stool types (stool consistency), and QoL. The
severity of abdominal pain and bloating was evaluated by
the patients using 10-cm Visual Analogue Scale (“nothing”
to “extremely intense”), and by the physicians using 5-point
Likert Scales (0: nothing, 1: mild, 2: moderate, 4: severe, and
5: very severe). Efficacy was considered to be achieved if the
difference (effect size) between treatment groups in terms of
severity of abdominal pain and/or bloating, assessed by the
patients (Visual Analogue Scale score), was at least 30%
(lower severity in the PB+S vs. placebo group) at V3. The
same criterion applied to physician’s assessment (Likert
Scales).
Stool consistency was assessed by both, the patients
(daily) and the physicians (at each visit, evaluating the last
7 d) using the Bristol Scale, which is an appropriate instru-
ment for capturing the stool consistency in IBS trials.34
Stool frequency was recorded in a diary that included the
stool-type pictograms of the Bristol Scale, thus patients
recorded each bowel movement according to the corre-
sponding stool type, as previously reported.33
To assess QoL, patients answered the Irritable Bowel
Syndrome Quality of Life (IBS-QOL) questionnaire at
randomization and at the end of treatment (V0 and V3,
respectively). The IBS-QOL is a self-administered
questionnaire35 that has been previously validated in
Spanish-Mexico.36 It includes 34 items summarized in 8
subscales: Dysphoria (DY), Interference with Activity (IN),
Body Image (BI), Health Worry (HW), Food Avoidance
(FA), Social Reaction (SR), Sexual (SX), and Relationships
(RL) and are combined for an Overall score (OV).
Safety
Standard laboratory tests for blood chemistry and
hematology were performed at inclusion (V0) and at
the end of treatment (V3). Blood chemistry included
serum creatinine, alkaline phosphatase, aspartate ami-
notransferase, alanine aminotransferase, and total bilir-
ubin. Hematology workup included hemoglobin and
blood cell count. All adverse events (AEs) and serious
adverse events (SAEs) were actively searched and recorded
during each study visit.
Statistical Analysis
For statistical analysis, 2 data sets were considered: a)
The intention to treat (ITT) data set, including all
randomized subjects who participated in at least 1 post-
baseline assessment, corresponding to V1 (n= 275); and the
per protocol (PP) data set, including all patients who did not
deviate from the planned protocol and were compliant with
at least 80% of the study medication (n= 216). Efficacy
analyses for the primary and secondary variables were
conducted with both ITT and PP data sets. For the ITT set,
missing values were imputed by maximum likelihood esti-
mation with regression of available repeated measurements
(for intermediate, not at random missing values) or by
last-observation-carried-forward method (if dropout). The
effect size for each data set is reported; however, no differ-
ences in effect sizes were observed between the ITT and PP
data sets (differences ranging from 0% to 2%) in all efficacy
variables.
Sample Size and Statistical Power
The standardized measure of effect size used in the
analysis of variance (ANOVA) was obtained by a root mean
square standardized effect.37 Parameters to calculate the
statistical power were obtained from a previous open-label
clinical trial with PB+S;33 the pooled mean change and SD
of abdominal pain severity score measured by the patients
(basal vs. final) was 1.5 ( ± 1.7), with a 0.5-point difference in
the mean. The α error was set at 0.05, and the estimated
effect size was 30%.
Descriptive demographics were expressed as mean±
SD. A factor analysis linked to a general linear model was
used to correct for confounding variables such as age, sex,
and BMI. Comparisons between fixed factors (treatment
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and IBS subtypes) were analyzed by multivariate ANOVA
for repeated measurements, incorporating the main out-
comes of all visits, using the Fisher post hoc test.
The effect size for overall symptom assessment,
abdominal pain, and bloating measured by the patient and
physicians, were calculated with partial η2 as follows (SS=
squared sums): η2p= SSEffect/SSEffect+SSError. The partial η2 is
used for ANOVA designs that have nonindependent meas-
urements. For easier interpretation, they were transformed
to Cohen d.38
The data from the Bristol Scale that were collected by the
physicians at each study visit were analyzed as relative
frequency distributions (density probability functions), and
weekly changes in consistency and frequency were further
analyzed according to the IBS subtype over the 12 weeks of
treatment. Only the IBS-C, IBS-D and IBS-M subtypes were
analyzed due to the high variability that was present in the
IBS-U group. Unweighted means of the weekly stool con-
sistency type x¼ P Typeð Þ  and frequency
x¼ P Frequencyð Þ  were estimated. Each curve was
smoothed for interpolation of the Bristol levels and then was
normalized to obtain a unity for the complete area under the
curve (AUC). Three segments were calculated (Bristol 1 to 3, 3
to 5, and 5 to 7). Treatment contrasts were based on the ratio
of AUC of the drug/placebo, and extraction of the null value
(=1) was conducted to draw the comparisons.
Finally, the score of each subscale of the IBS-QOL
Scale was calculated using an SPSS program syntax based
on the IBS-QOL scoring system. The raw score values were
transformed into percentages, which allowed calculating a
comparison dimension between subscales in spite of having
a different number of questions.
Ethics
The protocol was approved by an independent ethics
committee (Teaching, Research and Ethics Committee, Gen-
eral Hospital, Naucalpan-State of Mexico, Mexico), and the
study was conducted in accordance with the International
Conference on Harmonization, Guidelines for Good Clinical
Practices, Declaration of Helsinki, and applicable local regu-
lations. Before entry, all patients received detailed information
with regard to the study and signed informed consent.
RESULTS
Patients’ Baseline Characteristics
Between November 2008 and December 2009, 300
patients were screened. Sample attrition is depicted in
Figure 1. Fifteen patients were screen failure (10 because of
abdominal hysterectomy, 4 because of BMI > 35 kg/m2, and
1 because of age older than 50 y) and were excluded from
the analyses. Therefore, 285 were randomized and entered
the 12-week treatment period (women: 83%; age:
36.5 ± 8.9 y old; BMI: 26.7± 5 kg/m2) (Table 1). IBS-C was
the most frequent subtype (43.5%) followed by IBS-M
(31.2%), IBS-D (23.2%) and IBS-U (2.1%). The majority of
patients were from central Mexico and were similarly dis-
tributed into the treatment groups.
Among the 285 patients who entered the study, 30
withdrew prematurely (13 in the PB+S and 17 in the placebo
group) because of AEs (n= 1), SAEs (n= 2), lack of efficacy
(n=4), consent is withdrawn (n= 4), lost to follow-up
(n= 10), or noncompliance with the study treatment (n= 9)
(Fig. 1, Table 2).
FIGURE 1. Flowchart of patients through the study. AE indicates adverse event; ITT, intention to treat; PB+S, pinaverium bromide 100mg
plus simethicone 300mg; SAE, serious adverse event.
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Efficacy Results
Overall Symptom Improvement
There was a significant improvement over time in the
overall symptom assessment in both treatment groups.
However, the difference in effect size (Cohen d) between the
groups was a marginal 20% in favor of PB+S over placebo
both in the PP and ITT data sets (both, P= 0.13) and cor-
responding to a post hoc power of 20% for this endpoint
(Fig. 2).
Individual Symptoms
Patient assessment. PB+S was significantly superior to
placebo (P= 0.04) in improving the severity of abdominal
pain, with a total effect size of 30% (ITT: 29%, PP: 31%)
(Fig. 3A), and with regard to the severity of bloating
(P= 0.02), with an effect size of 33% (ITT: 32%, PP: 33%)
(Fig. 3B).
Physician assessment. Abdominal pain showed the highest
difference between PB+S and placebo (P= 0.009), with an
effect size of 36% favoring PB+S (ITT: 36%, PP: 36%)
(Fig. 4A). As for bloating severity, the results were not
significant (P= 0.09), with a marginal total effect size of
26% (PP: 26%, ITT: 26%) (Fig. 4B).
Stool Consistency
Frequency distribution. Patients with IBS-C presented a clear
predominance of Bristol types 1 and 2 at baseline (Figs. 5A,
B). During the first 4 weeks of treatment, a shift to the right,
toward type 4 was observed, and the peak progressively
sharpened in the PB+S group (Fig. 5A). The placebo group
showed a less sharpened peak curve, and differences between
visits were less noticeable (Fig. 5B). Thus, patients with IBS-C
receiving PB+S showed a clear improvement.
In IBS-D, the frequency distribution of the Bristol stool
types at baseline was skewed to the right toward types 5 to 7
(Figs. 5D, E). Once the treatment started, the curves were
displaced toward the left, showing a Bristol stool type cen-
tered over type 4 from week 8 onwards (Fig. 5E). It is worth
mentioning that, despite the shift to the left, some subjects
with Bristol types 6 and 7 remained as such, but with a lower
frequency than at baseline. Both treatment groups showed a
similar behavior; notwithstanding, the decrease in the
TABLE 2. Reasons For Patients’ Premature Withdrawal From the Study
Causes PB+S (n, Event) Placebo (n, Event) Total (n)
AEs None 1, lower limb paresthesia 1
SAEs 1, acute pancreatitis plus hypertriglyceridemia 1, brain aneurism 2
Lack of efficacy None 3, nonperceived efficacy
1, increased abdominal bloating
4
AE indicates adverse event; PB+S, pinaverium bromide 100 mg plus simethicone 300 mg; SAE, serious adverse event.






Female/male ratio (n)* 118/22 119/26 0.99
First-time consulting* 65 (46.4) 54 (37.2) 0.12
Age (y)† 35.3 (8.8) 36.5 (9.0) 0.24
Waist circumference (cm)† 90.3 (11.9) 90.1 (10.9) 0.91
Body mass index (kg/m2)† 26.3 (4.5) 26.7 (5.9) 0.54
Heart rate (beats/min)† 73.6 (6.7) 74.4 (7.8) 0.37
Respiratory rate
(breaths/min)†
17.6 (1.8) 17.6 (1.8) 0.84
Temperature (°C)† 36.3 (0.4) 36.4 (0.5) 0.08
Systolic BP (mmHg)† 112 (12.3) 114.2 (12.6) 0.13
Diastolic BP (mmHg)† 70.7 (9.0) 72.9 (9.4) 0.04
IBS subtypes*
IBS-C 62 (44.3) 62 (42.8) 0.99
IBS-D 32 (22.9) 34 (23.4)
IBS-M 43 (30.7) 46 (31.7)
IBS-U 3 (2.1) 3 (2.1)
Geographic area*
Northern Mexico 28 (20.9) 33 (23.7) 0.39
Central Mexico 59 (44.0) 68 (48.9)
Southern Mexico 47 (35.1) 38 (27.3)
Physician specialties*
Gastroenterologists 71 (52.2) 82 (57.3) 0.57
Endoscopic surgeons 28 (20.6) 23 (16.1)
General surgeons 37 (27.2) 38 (26.6)
Basal characteristics of randomized patients according to the treatment
groups.
*Categorical variables are expressed as n (%) and contrast with the
χ2 test.
†Data are expressed as mean (SD), and were contrasted with the Student
t test adjusted for homoscedasticity.
BP indicates blood pressure; IBS, irritable bowel syndrome; IBS-C, irri-
table bowel syndrome with constipation; IBS-D, irritable bowel syndrome
with diarrhea; IBS-M, mixed-type irritable bowel syndrome; IBS-U, unsub-
typed irritable bowel syndrome; PB+S, pinaverium bromide 100 mg plus
simethicone 300 mg.
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FIGURE 2. Overall irritable bowel syndrome symptom assessment
by the patients. Values represent the mean overall improvement
scores graded weekly by the patients using a Likert Scale. The
total effect size reported as Cohen d was 20% between the
treatment groups (P=0.13). Data are expressed as mean± SEM.
V0=baseline visit, V1=4 weeks of treatment, V2=8 weeks of
treatment, and V3=12 weeks. PB+S indicates pinaverium bro-
mide 100mg plus simethicone 300mg.
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frequency for the remnant Bristol types 6 and 7 was slightly
larger with PB+S (Fig. 5D).
Patients with IBS-M showed a trimodal baseline curve,
with 1 peak on types 1 and 2, the second peak on types 3 to 5,
and a third one (the most frequent) on types 6 and 7 (Fig. 5G).
The frequency curves shifted rapidly toward the center for
both treatment groups (Figs. 5G, H); however, the PB+S
group remained with significantly greater dispersion than the
placebo group at the end of the treatment period.
Relative changes. In the IBS-C group, there was a decrease
of at least 20% in Bristol 1 to 3 segments of the AUC and a
significant increase of Bristol 5 to 7 segments in favor of PB
+S (Fig. 5C). In the IBS-D, there was a decrease in the
Bristol 1 to 3 segments in favor of placebo (Fig. 5F),
whereas in IBS-M, there was a slight increase in Bristol 5 to
7 segments of the AUC, favoring PB+S (Fig. 5I).
IBS-QOL
All subscales and the OV score of the IBS-QOL
improved significantly in both treatment groups without any
significant difference between them (Table 3).
Safety Evaluation
Only 3.6% of the total sample (11/300) reported ≥ 1
AEs, 3.3% (5/150) in the PB+S group and 4% (6/150) in the
placebo group. At least 1 non-SAE was reported by 5
patients in the PB+S group and by 6 patients in the placebo
group. Only 2 patients experienced SAEs, corresponding to
1 patient in each treatment group (a case of acute pan-
creatitis in the active group and a brain aneurism in the
placebo group); both withdrew from the study prematurely
for these reasons (Table 2). They represented 0.6% (1/150) of
each group. The case of acute pancreatitis was not consid-
ered to be related to the study medication.
DISCUSSION
This study demonstrates for the first time in a con-
trolled trial in IBS-Rome III, the efficacy of the combination
of PB+S over placebo in the treatment of abdominal pain
and bloating assessed by the patients. Although there were
no differences between PB+S and placebo on the overall
symptom improvement of IBS, the primary outcome
Weeks

























































FIGURE 3. Severity of abdominal pain and bloating assessed by the patients. Numbers represent the mean values of abdominal pain (A)
and bloating (B) severity graded weekly by the patients with a 10-cm VAS. The total effect size reported as Cohen d was 31% for pain
(P=0.038) and 33% for bloating (P=0.019), both favoring PB+S over placebo. Data are expressed as mean± SEM. V0=baseline visit,
V1=4 weeks of treatment, V2=8 weeks of treatment, and V3=12 weeks. PB+S indicates pinaverium bromide 100mg plus simethicone
300mg; VAS, Visual Analogue Scale.




























































FIGURE 4. Severity of abdominal pain and bloating assessed by the physicians. Numbers represent the mean values of abdominal pain
(A) and bloating (B) severity assessed by the physicians using 5-point Likert Scales. The baseline adjusted score (analysis of covariance)
was 2.8. The total effect size was 36% for pain (P<0.009) and 26% for bloating (P<0.09), both favoring PB+S over placebo. Data are
expressed as mean± SEM. V0=baseline visit, V1=4 weeks of treatment, V2=8 weeks of treatment, and V3=12 weeks. PB+S indicates
pinaverium bromide 100mg plus simethicone 300mg.
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measure of this trial, using the frequency distribution of
Bristol stool types (consistency), PB+S produced a shift
toward Bristol stool types 3 to 5, mainly in the IBS-C and
IBS-M patients. Finally, there were no differences in the
IBS-QOL scores between the groups, and PB+S was safe
and well-tolerated.
Because of the high response to placebo in previous IBS
clinical trials, which has been reported in 37.5% (95% CI: 34.4,
40.6),39 we carried out the present study analyzing several
clinical outcomes addressed to evaluate the response to a
combined treatment, PB+S. Among the different outcomes
that we analyzed, there were scales that were assessed by the
patients using diaries to evaluate any changes in the day before
and scales that were assessed by the physician-investigators
while interviewing the patients. Although there was no differ-
ence in the overall symptom improvement, the main outcome
measure, it is interesting that PB+S was effective on the
severity of individual symptoms such as abdominal pain and
bloating. The effect size for the severity of abdominal pain
reached 31% when evaluated by the patients, which is slightly
higher than that reported in other clinical trials in IBS,40 and
36% when assessed by physician-investigators with similar
figures for bloating, independently of the IBS subtype. These
results support the current trend in clinical trials on IBS, for
using more objective scales to assess specific symptoms such as
abdominal pain, bloating, and stool consistency, as overall
outcome measures may be too subjective.41–43
The effect size of different monotherapies compared with
placebo in different diseases has been previously analyzed in
several meta-analyses. Achievement of effect sizes >30% are of
relevance particularly for treatments addressing functional gas-


























































































































































































































































































FIGURE 5. Frequency distribution of the BSFS stool types according to IBS subtypes and treatment groups. The density function of
probability for each IBS subtype and changes by visits (from A, B, D, E, G, and H) are shown with solid black lines (baseline). Relative
differences between placebo and PB+S can be seen on the right side bar figures [IBS-C (C); IBS-D (F); IBS-M (I)]. The clusters of 3 bars
represent V1 to V3 for each segment of the AUC. A change of 0.2 at the “y” axis represents at least 20% change. The positive values
(upper directions of the bars) are in favor of PB+S treatment, and the negative values (lower directions of the bars) represent an
incremental AUC in favor of placebo. These changes must be compared with the left figures (A, B, D, E, G, and H) to understand the
dynamics of the AUC functions. AUC indicates area under the curve; BSFS, Bristol Stool Form Scale; IBS, irritable bowel syndrome; IBS-C,
irritable bowel syndrome with constipation; IBS-D, irritable bowel syndrome with diarrhea; IBS-M, mixed-type irritable bowel syndrome;
PB+S, pinaverium bromide 100mg plus simethicone 300mg.
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attributable to placebo can be expected.44,45 Some meta-analy-
ses on IBS have included a wide variety of antispasmodics using
ORs as a measurement of differences. However, the effect index
of such data can be transformed into Cohen d for comparison
with our current data.38,46,47 Accordingly, fiber and tegaserod
have previously shown effect sizes of around 19%. Other com-
monly used treatments, such as antispasmodics, have shown
effect sizes ranging between 28 and 35%, whereas anti-
depressants reach effect sizes of around 35%.48,49
The significant effect on bloating with PB+S inde-
pendently of the bowel habit subtype shown in the present
study, is an important one, as few treatments have proven to
be effective on this common symptom,50 and all of them
including newer treatments are effective on specific IBS
subtypes such as linaclotide in IBS-C.51,52 The improvement
of bloating may have been exerted by the additional effect of
the antifoaming S with the smooth muscle relaxant prop-
erties of PB. In fact, a systematic review and meta-analysis
of antispasmodics available in Mexico reported that only
the PB+S combination was effective on bloating.53 Further,
PB+S also improved abdominal pain in the current study. In
earlier preclinical studies, intragastric administration of PB
in rats decreased the abdominal cramps in response to dis-
tensions of the proximal colon, supporting its effect on
visceral pain. Thus, it is plausible to believe that the com-
bination of PB with S helps in relieving both symptoms.
This is not the first trial using combination therapy for IBS,
and our results are in agreement with those of an on-
demand trial using alverine citrate also combined with
simethicone, showing similar effects on bloating and
abdominal pain.54
The effect of PB+S in the higher frequency of Bristol
stool types 3 to 5, mainly in the IBS-C and IBS-M patients,
which was observed in the present study, is another impor-
tant finding. One may speculate that the high dose (300 mg)
of S used in the current trial helps patients to increase the
frequency of bowel movements by dissolving the gas bub-
bles, thus facilitating bowel movements. The density func-
tion of stool types, which are shown for weekly probabilities
used in the current trial (Fig. 5), may be useful for simu-
lation analysis, as each IBS subtype shows a different pat-
tern of response to active treatment and placebo when
Bristol stool types are used. This density function allows
dynamic changes expressed as an increase in relative
frequency toward the center of the curve to be observed
while treatment time is passing. It is clear that important
changes occur in short periods of time, even days, for all IBS
subtypes, and then they stabilize around Bristol types 3 to 5.
The fact that we included patients within the age range
of 18 years or above and 50 years or below is a limitation, as
the efficacy of the PB+S cannot be extrapolated to IBS
patients older than 50 years of age. However, in a previous
multicenter epidemiological study conducted in Mexico in
the same clinics from which the patients for the current
study were enrolled, we found a mean age of the IBS-Rome
III patients to be at 36.9 ± 8.8 years old.55 Moreover, the
proportion of men with colorectal cancer increases dra-
matically from the age of 50 years old and on, and roughly,
90% of colon cancer occurs in people older than this age
despite their ethnic origin.56–58 Furthermore, although
patients with alarm symptoms, known organic diagnoses, or
malignancy were excluded from the current trial, endoscopic
examination (either upper endoscopy and/or colonoscopy)
was optional at the investigator’s discretion. Therefore,
using the inclusion criteria of individuals below the cutoff
age of 50 years, reasonably avoided any risk of confounders
associated with age in the studied sample.
In conclusion, the combined therapy that includes PB
+S has proven to be effective for the treatment of IBS. This
study supports the concept that a treatment combination is a
convenient approach for the treatment of IBS. Future
analyses in clinical trials should include these kinds of
methodologies for efficacy toward understanding the
mechanism of improvement according to the IBS subtypes.
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